Menu

WIKIMEDIA, NIH

Francis Collins Pranked by Sacha Baron Cohen

Duped into an interview with the comedian, the NIH director caught on to the joke and seized it as a teaching opportunity.

Aug 24, 2018
Ashley Yeager

A few minutes into an interview with a “journalist” from a Showtime special, Francis Collins, the director of the National Institutes of Health, sensed something wasn’t quite right.

“Why are big agriculture putting chemicals [trans fats] into our food to make people transgender?” asked the interviewer, who called himself Billy Wayne Ruddick Jr., PhD.

“Yeah, that was interesting,” Collins tells reporters, according to STAT News. “That interview was done last November and was presented as a Showtime special where the interviewer is somebody who doesn’t know a lot about medical research, but gives you a chance to talk about the exciting things that are happening at NIH. Sounds like a plausible thing that I’d want to do.”

That’s not exactly what happened, however. “It was pretty clear that this was not the usual circumstance,” Collins says. Ruddick was actually comedian Sacha Baron Cohen in disguise for “Who Is America,” a political satire show. “But I decided, just play it straight. And you saw the result. Actually, you saw three minutes of about an hour of a very interesting conversation.” Collins’s interview with Ruddick aired on Showtime on Sunday (August 19).

The joke on Collins didn’t land perfectly, according to critics. “Sure, some of Cohen’s jokes as Ruddick landed well in this segment, but the world would be a better place if Collins were off studying the human genome instead of wasting his time here,” Josh Modell writes in Vulture.

Collins considered ending the interview early, but, “I thought, maybe there’s a public health message that could get wrapped in here. And there was a bit, about trans fats and needle sharing. So there you go.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.